Cholangiocarcinoma
Cholangiocarcinoma is a cancer that arises from the cells lining the bile ducts—the channels that carry bile from the liver to the small intestine. It is grouped by location into intrahepatic (within the liver), perihilar (at the junction of the right and left hepatic ducts, also called Klatskin tumors), and distal (in the lower bile duct) cholangiocarcinoma. It is uncommon but increasingly recognized. Risk factors include chronic biliary inflammation, primary sclerosing cholangitis, liver flukes, certain congenital biliary conditions, hepatitis B and C, cirrhosis, and obesity. MRI with cholangiography, CT, endoscopic studies, and biopsy are central to diagnosis, and management is highly individualized.
What is it?
Bile is a fluid produced by the liver that helps digest fats and remove waste products from the body. Bile flows from the liver through a branching network of bile ducts that eventually combine and drain into the duodenum (the first part of the small intestine). Cholangiocarcinoma is a cancer that arises from the cells lining these bile ducts. It is a relatively uncommon but clinically important cancer, with a rising incidence in many parts of the world.
Cholangiocarcinoma is grouped by anatomical location into three main types. Intrahepatic cholangiocarcinoma develops in bile ducts within the liver itself and often presents as a liver mass. Perihilar cholangiocarcinoma—sometimes called a Klatskin tumor—occurs at the junction where the right and left hepatic ducts come together to form the common hepatic duct; this is the most common location. Distal cholangiocarcinoma arises in the lower portion of the bile duct as it travels through the head of the pancreas and into the duodenum. Each location has distinct clinical features, management approaches, and outcomes.
Several risk factors increase the likelihood of cholangiocarcinoma, although many patients have no identifiable risk factor. Chronic inflammation of the bile ducts is a common theme. Primary sclerosing cholangitis (PSC), an autoimmune disease that causes scarring of the bile ducts, is a major risk factor and may warrant ongoing surveillance. Liver fluke infections (such as Opisthorchis viverrini and Clonorchis sinensis) are major risk factors in endemic regions of Southeast Asia. Hepatitis B and C, cirrhosis from any cause, and steatotic liver disease are also recognized contributors. Certain congenital biliary conditions—including choledochal cysts and Caroli disease—predispose to cholangiocarcinoma over time. Other contributors include hepatolithiasis (bile duct stones), prior exposure to certain chemicals or radiation, inflammatory bowel disease (often through its association with PSC), diabetes, obesity, and smoking.
Symptoms often develop gradually and depend on tumor location. Perihilar and distal cholangiocarcinomas tend to obstruct bile flow and commonly present with painless jaundice (yellowing of the skin and eyes), dark urine, pale or clay-colored stools, and itching—often with relatively few other early symptoms. Intrahepatic cholangiocarcinoma is more likely to present as an upper abdominal mass causing vague pain or fullness, weight loss, or fatigue, sometimes without jaundice until later. Other possible symptoms include loss of appetite, fevers and chills (from cholangitis when bile flow is blocked), nausea, and a general sense of being unwell. In more advanced disease, ascites, leg swelling, and signs of liver dysfunction can occur.
Diagnosis combines clinical assessment, laboratory tests, and imaging. Blood tests typically show abnormal liver function with elevated bilirubin and alkaline phosphatase, particularly in patients with biliary obstruction. Tumor markers such as CA 19-9 and CEA may be elevated, although they are not specific. Ultrasound of the abdomen often identifies bile duct dilation or a liver mass. CT with intravenous contrast provides detailed information about a liver mass, bile duct anatomy, vascular involvement, and spread of disease, and is widely used for staging and surgical planning. MRI with MR cholangiopancreatography (MRCP) is particularly valuable for evaluating the bile ducts, characterizing the tumor, and assessing the extent of disease. Endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous transhepatic cholangiography allow direct imaging of the bile ducts, sampling for cytology or biopsy, and therapeutic procedures such as biliary drainage. Endoscopic ultrasound provides high-resolution imaging and can guide fine-needle biopsy. Tissue diagnosis is generally required before definitive treatment, although in selected patients—particularly those being considered for transplantation—the approach to biopsy is highly individualized. Molecular testing is increasingly used in advanced disease to identify actionable targets such as FGFR2 fusions, IDH1 mutations, BRAF mutations, HER2 amplification, and microsatellite instability.
Important to Know
Treatment of cholangiocarcinoma is highly individualized and depends on the location, stage, molecular features, the patient’s overall health, and the involvement of nearby vessels and organs. Care is typically coordinated by multidisciplinary teams that may include hepatobiliary surgeons, medical and radiation oncologists, hepatologists, interventional radiologists, gastroenterologists, pathologists, palliative care specialists, and others.
Surgical resection offers the best chance for long-term control or cure but is feasible only in a subset of patients. For intrahepatic cholangiocarcinoma, this typically involves liver resection. For perihilar cholangiocarcinoma, treatment often involves extensive surgery that may include resection of part of the liver, the bile ducts, and sometimes the gallbladder and regional lymph nodes. Distal cholangiocarcinoma is typically treated with pancreaticoduodenectomy (the Whipple procedure). In carefully selected patients with perihilar cholangiocarcinoma—particularly those with PSC and early-stage disease—liver transplantation combined with neoadjuvant chemoradiation can offer favorable outcomes at experienced centers. Adjuvant chemotherapy after surgery is now standard in many situations and is associated with improved outcomes.
For patients who are not candidates for surgery or who have advanced disease, systemic therapy is the cornerstone of treatment. Standard first-line chemotherapy typically includes combinations such as gemcitabine plus cisplatin, often with the addition of immunotherapy in eligible patients. Targeted therapies are increasingly important: FGFR2 inhibitors, IDH1 inhibitors, HER2-targeted therapies, BRAF/MEK inhibitors, and immunotherapy for microsatellite instability or high tumor mutational burden are now used based on molecular testing. Radiation therapy and locoregional treatments—such as transarterial chemoembolization, radioembolization, and ablation—are options for selected patients, particularly with intrahepatic disease.
Management of biliary obstruction is a critical part of care. Endoscopic or percutaneous biliary drainage with stent placement relieves jaundice, reduces itching, prevents and treats cholangitis, supports nutrition, and is often essential before chemotherapy or surgery. Multidisciplinary planning of biliary drainage in perihilar disease is particularly important.
Supportive and palliative care play important roles throughout the course of disease. This includes pain management, nutritional support, treatment of itching, management of fatigue, support for psychological wellbeing, and family-centered care planning. Early integration of palliative care—even alongside active cancer treatment—is associated with improved quality of life.
Patients with primary sclerosing cholangitis benefit from ongoing surveillance imaging and laboratory monitoring for cholangiocarcinoma and other complications. Patients with congenital biliary conditions such as choledochal cysts or Caroli disease may also require ongoing follow-up.
Care is best provided in centers with experience in hepatobiliary cancers and the full range of medical, surgical, interventional, and radiation treatments. Imaging and laboratory findings are interpreted alongside the patient’s symptoms, examination, and broader clinical context rather than in isolation.
Red flag symptoms include rapidly progressive jaundice, severe upper right abdominal pain, high fever with chills, severe vomiting, significant unintentional weight loss, signs of gastrointestinal bleeding (such as blood in vomit or stool), confusion or sleep changes, severe abdominal swelling, or signs of sepsis or shock. These warrant prompt or urgent medical evaluation, as they may indicate cholangitis, biliary obstruction, or other serious complications.